Protagonist Therapeutics (NASDAQ:PTGX) Given New $113.00 Price Target at Barclays

Protagonist Therapeutics (NASDAQ:PTGX) had its target price upped by Barclays from $108.00 to $113.00 in a report issued on Thursday morning,Benzinga reports. Barclays currently has an overweight rating on the stock.

PTGX has been the topic of several other reports. Weiss Ratings lowered Protagonist Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, February 17th. Truist Financial raised their target price on shares of Protagonist Therapeutics from $88.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, January 5th. Jefferies Financial Group lifted their target price on shares of Protagonist Therapeutics from $95.00 to $118.00 and gave the stock a “buy” rating in a research note on Monday, February 2nd. HC Wainwright increased their price target on shares of Protagonist Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a research report on Friday, January 30th. Finally, JPMorgan Chase & Co. raised their price target on shares of Protagonist Therapeutics from $68.00 to $81.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $99.31.

Protagonist Therapeutics Stock Performance

Shares of Protagonist Therapeutics stock opened at $88.39 on Thursday. Protagonist Therapeutics has a 52-week low of $35.95 and a 52-week high of $96.54. The company has a fifty day moving average of $84.12 and a 200-day moving average of $76.59. The stock has a market capitalization of $5.53 billion, a price-to-earnings ratio of -43.12 and a beta of 2.26.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.16). Protagonist Therapeutics had a negative return on equity of 19.50% and a negative net margin of 282.83%.The business had revenue of $7.44 million during the quarter, compared to the consensus estimate of $14.92 million. On average, equities research analysts forecast that Protagonist Therapeutics will post 2.43 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Dinesh V. Ph D. Patel sold 34,438 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $82.48, for a total value of $2,840,446.24. Following the completion of the sale, the chief executive officer directly owned 580,505 shares of the company’s stock, valued at approximately $47,880,052.40. This trade represents a 5.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Asif Ali sold 46,203 shares of the stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $83.13, for a total transaction of $3,840,855.39. Following the completion of the transaction, the chief financial officer directly owned 60,320 shares of the company’s stock, valued at approximately $5,014,401.60. The trade was a 43.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 203,167 shares of company stock worth $16,889,199. Company insiders own 4.90% of the company’s stock.

Hedge Funds Weigh In On Protagonist Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC boosted its holdings in shares of Protagonist Therapeutics by 110.6% during the 4th quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock valued at $26,000 after buying an additional 156 shares in the last quarter. Greenline Wealth Management LLC purchased a new position in Protagonist Therapeutics during the 4th quarter valued at about $27,000. Bessemer Group Inc. boosted its stake in Protagonist Therapeutics by 171.0% during the second quarter. Bessemer Group Inc. now owns 504 shares of the company’s stock worth $28,000 after acquiring an additional 318 shares in the last quarter. Salomon & Ludwin LLC purchased a new stake in Protagonist Therapeutics in the third quarter worth about $29,000. Finally, CWM LLC increased its stake in shares of Protagonist Therapeutics by 201.5% during the second quarter. CWM LLC now owns 609 shares of the company’s stock valued at $34,000 after purchasing an additional 407 shares in the last quarter. Institutional investors own 98.63% of the company’s stock.

Trending Headlines about Protagonist Therapeutics

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: Several brokers raised ratings and price targets this morning, signaling renewed analyst conviction (higher targets increase upside perception). Barclays raised its target to $113 and kept an “overweight” rating. Barclays Raises PT to $113
• Positive Sentiment: Citizens JMP bumped its target to $112 and maintained a “market outperform” view, adding to the upward pressure on investor expectations. Citizens JMP Raises PT to $112
• Positive Sentiment: TD Cowen raised its target to $100 and reaffirmed a “buy” rating, giving additional dealer support for further gains. TD Cowen Raises PT to $100
• Positive Sentiment: Company corporate update: Protagonist submitted an NDA for rusfertide to the FDA (potential approval/launch this year), expects a U.S. regulatory decision for ICOTYDE (icotrokinra) in 2026 with potential launch, may opt out of a 50:50 profit/loss sharing deal with Takeda (90‑day window expected in Q2), expects PN‑881 Phase 1 completion by mid‑2026, and expanded its preclinical pipeline — all items that materially improve medium‑term commercial and revenue prospects. Corporate Update / Correction
• Neutral Sentiment: Press coverage and earnings snapshot pieces summarizing the quarter and corporate update provide broader market context but add no new facts beyond the company release. Q4 Earnings Snapshot
• Negative Sentiment: Q4 results missed expectations: reported EPS of ($0.69) vs. consensus ($0.53) and revenue $7.44M vs. $14.92M est. The revenue shortfall and EPS miss add short‑term execution risk and raise questions about near‑term cash flow. Q4 Results / Press Release
• Negative Sentiment: Hedge fund BVF disclosed a large Q4 exit, selling ~2.56M PTGX shares (≈$170M at quarter‑end), which could increase supply pressure if other holders follow. BVF Share Sale

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.